BeiGene, Ltd. (ONC)vsPropanc Biopharma, Inc. Common Stock (PPCB)
ONC
BeiGene, Ltd.
$282.72
+0.15%
HEALTHCARE · Cap: $32.42B
PPCB
Propanc Biopharma, Inc. Common Stock
$0.12
+1.45%
HEALTHCARE · Cap: $1.86M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
PPCB
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1999.6%
Fair Value
$16.73
Current Price
$282.72
$265.99 premium
Margin of Safety
N/A
Fair Value
$354.35
Current Price
$0.12
$354.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : PPCB
The strongest argument for PPCB centers on Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 114.8x leaves little room for execution misses.
Bear Case : PPCB
The primary concerns for PPCB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while PPCB is a value play — different risk/reward profiles.
PPCB carries more volatility with a beta of 3.48 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 26/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Propanc Biopharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?